Drug intelligence / Profile preview

clonazepam + escitalopram

Development stage: Unknown
Lead developer: Sinsan Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**CAMDEM** is an oral fixed-dose combination tablet marketed by Sinsan Pharmaceuticals containing clonazepam and escitalopram oxalate. Clonazepam is a benzodiazepine that enhances inhibitory gamma-aminobutyric acid signaling, while escitalopram is a selective serotonin reuptake inhibitor that increases serotonergic neurotransmission. CAMDEM is marketed for anxiety disorders, including anxiety with depressive symptoms; listed strengths include clonazepam 0.5 mg with escitalopram 5 mg or 10 mg. ([1mg.com](https://www.1mg.com/medicines/camdem-71194))

Brand names: CAMDEM
Other names: clonazepam + escitalopram oxalate

Targets

GABRR (GABA-A receptor subunit rho)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on clonazepam + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clonazepam + escitalopram.

Explore the full profile